Despite the success of antiretroviral therapy (ART) for people living with HIV, lifelong
treatment is required and there is no cure. HIV can integrate in the host genome and persist …

The ubiquitin system is complex, multifaceted, and is crucial for the modulation of a vast
number of cellular processes. Ubiquitination is tightly regulated at different levels by a range …

HIV-1 persists in a latent reservoir in resting CD4+ T cells despite antiretroviral therapy
(ART). The reservoir decays slowly over the first 7 years of ART (t 1/2= 44 months). However …

Brain microglia (MG) may serve as a human immunodeficiency virus 1 (HIV) reservoir and
ignite rebound viremia following cessation of antiretroviral therapy (ART), but they have yet …

Various forms of cell death have been identified over the last decades with each relying on a
different subset of proteins for the activation and execution of their respective pathway (s). In …

The main barrier to HIV cure is a persistent reservoir of latently infected CD4+ T cells
harboring replication-competent provirus that fuels rebound viremia upon antiretroviral …

Antiretroviral therapy (ART) inhibits HIV replication but is not curative. During ART, the
integrated HIV genome persists indefinitely within CD4+ T cells and perhaps other cells …

The development of antiretroviral therapy for the prevention and treatment of HIV infection
has been marked by a series of remarkable successes. However, the efforts to develop a …

Human immunodeficiency virus type 1 (HIV-1) infection persists despite years of
antiretroviral therapy (ART). To remove the stigma and burden of chronic infection …

Combinatory antiretroviral therapy (cART) reduces human immunodeficiency virus type 1
(HIV-1) replication but is not curative because cART interruption almost invariably leads to a …